WHO ICTRP trial
Evaluation of the effectiveness of oxytocin by placebo nasal spray on symptoms…
IRCT20200404046938N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200404046938N1 |
|---|---|
| Public title | Evaluation of the effectiveness of oxytocin by placebo nasal spray on symptoms and treatment of adults with autism |
| Scientific title | Comparison of the effectiveness of oxytocin nasal spray with placebo on symptoms and treatment of adults with autism: a randomized clinical trial |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Autistic Disorder. Autistic disorder;F84.0 |
| Interventions | Intervention 1: Intervention group: Oxytocin nasal spray, including oxytocin peptide, 25 ml bottle, 2 times a day, two puffs in each nostril, including 48 international units of oxytocin daily, for 8 weeks, Pharma Globe (Pharma Grid) UK… |
| Registration date | Feb 19, 2022 |
| Target size | 40 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: